General Comments / Chat, page-63

Yes there is a lot of low hanging fruit in repurposing existing drugs for new indications. The difficulty can be that many of these newly discovered drugs hit a very limited subset of cancer sub-types. This can make it really hard to make a commercial drug out of these discoveries as the market can be tiny. Having a drug like Bisantrene that works on a wide variety of cancers is really, really useful when you are trying to get a large Pharma company to financially support the Phase III trials needed to bring a drug to market.

I have to sit down and read the original paper in depth. Here is the link for those interested.

https://www.nature.com/articles/s43018-019-0018-6